Accurate computational model of the electrical behavior of the human heart

April 2, 2014 by Jennifer Nachbur
Accurate computational model of the electrical behavior of the human heart
Peter Spector, M.D., Professor of Medicine and Director of Electrophysiology at Fletcher Allen Health Care. Credit: Jeff Clarke

Physician scientists can find inspiration – and solutions – in every corner of an academic medical center: the clinic, the research arena, or while teaching. That's how Peter Spector, M.D., a University of Vermont professor of medicine and director of electrophysiology at Fletcher Allen Health Care, came to co-develop – with Professor of Medicine and engineer Jason Bates, Ph.D. – a three-dimensional computational model of a human heart called Visible EP.

The software technology that Spector and Bates built is as remarkable as their collaboration. Spector came to the table with the vision of the final product and a deep understanding of and how the heart works, but was unfamiliar with the programming process. Bates possessed programming skills and expertise in computational models. Together, they produced a technology that very accurately models the electrical behavior of the , to the smallest level of detail.

Bates and Spector created Visible EP (which stands for "electrophysiology") as a means to gain a better understanding of how to cure the most common abnormal heart rhythm – atrial fibrillation (AF) – which afflicts more than five million people in the U.S. alone. To date, says Spector, treatment has been less than adequate.

The result of their teamwork is a program that mimics the behavior of the heart from every aspect, as well as features the ability to provide unpredictable responses – a phenomenon called emergent behavior. While the parts of the heart and the rules of interaction have been programmed into the system, the computational heart model's reaction is entirely emergent, says Spector.

"We've made, essentially, a living, breathing, interactive human heart," he says. "It will sit there and beat in what would be the equivalent of a normal rhythm; you can induce every sort of that you can imagine that a patient could have, and it's all happening on a computer screen."

Visible EP's emergent behavior feature makes it an attractive tool for medical education, as well as research applications. Because it can't be readily seen, electrophysiology has been regarded as a particularly difficult specialty to teach; the field was waiting for just such a teaching tool as Visible EP.

Spector and Bates were recognized with an award for licensing Visible EP at the 2013 Vermont Invention to Venture conference, an annual day-long event co-organized by UVM's Office of Technology Commercialization. In summer 2013, Spector officially set up shop as founder and director of his spinoff, Visible Electrophysiology, LLC, a medical simulation company whose staff includes a chief technology officer and educational product manager at Visible EP.

Spector uses the Visible EP technology in his arrhythmia research lab, where his team consists of three biomedical engineering doctoral students and a postdoctoral MD research fellow. Using this computer model, combined with studies of the real human heart, the group has proposed a new approach to analyzing an individual patient's electrical activity and to using this information to guide a new type of ablation. In addition, the team has developed a new catheter, signal processing algorithms and a mapping approach for treatment of AF. This work has been sponsored by a generous grant from the Evslin Foundation and has led to the submission of eight patent applications through the University's Office of Technology Commercialization.

Explore further: UCSD uses heat energy to fix odd heart beat

Related Stories

UCSD uses heat energy to fix odd heart beat

February 17, 2012
(Medical Xpress) -- UC San Diego Sulpizio Cardiovascular Center is now offering patients with atrial fibrillation the breakthrough benefits of heat energy, or radio frequency waves, to irreversibly alter heart tissue that ...

High frequency source ablation effective in treating atrial fibrillation

November 20, 2013
High frequency source ablation is as safe and effective as a more standard ablation treatment for patients with paroxysmal atrial fibrillation, according to a late-breaking clinical trial presented at the American Heart Association's ...

Natural compound attacks HER2 positive breast cancer cells

February 18, 2014
(Medical Xpress)—A common compound known to fight lymphoma and skin conditions actually has a second method of action that makes it particularly deadly against certain aggressive breast tumors, researchers at Duke Medicine ...

Recommended for you

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.